CMBL

Summary

CMBL (carboxymethylenebutenolidase homolog, HGNC:25090) is a protein-coding gene on chromosome 5p15.2, encoding Carboxymethylenebutenolidase homolog (Q96DG6). Cysteine hydrolase whose endogenous substrates and physiological function are unknown.

CMBL (EC 3.1.1.45) is a cysteine hydrolase of the dienelactone hydrolase family that is highly expressed in liver cytosol. CMBL preferentially cleaves cyclic esters, and it activates medoxomil-ester prodrugs in which the medoxomil moiety is linked to an oxygen atom (Ishizuka et al., 2010 [PubMed 20177059]).

Source: NCBI Gene 134147 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 62 total — 2 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_138809

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25090
Approved symbol	CMBL
Name	carboxymethylenebutenolidase homolog
Location	5p15.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23617
Ensembl gene	ENSG00000164237
Ensembl biotype	protein_coding
OMIM	613379
Entrez	134147

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 21 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron

ENST00000296658, ENST00000503834, ENST00000506224, ENST00000506821, ENST00000510532, ENST00000511963, ENST00000514202, ENST00000873539, ENST00000873540, ENST00000873541, ENST00000873542, ENST00000873543, ENST00000873544, ENST00000873545, ENST00000873546, ENST00000873547, ENST00000873548, ENST00000873549, ENST00000873550, ENST00000873551, ENST00000873552, ENST00000873553, ENST00000873554, ENST00000873555, ENST00000873556, ENST00000873557, ENST00000941395

RefSeq mRNA: 1 — MANE Select: NM_138809 NM_138809

CCDS: CCDS3878

Canonical transcript exons

ENST00000296658 — 6 exons

Exon	Start	End
ENSE00001266385	10277595	10280632
ENSE00001315089	10307625	10307902
ENSE00003475769	10290548	10290781
ENSE00003501504	10286354	10286496
ENSE00003510720	10282197	10282288
ENSE00003603908	10288422	10288529

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 99.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.2050 / max 385.0840, expressed in 1530 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
60890	16.6116	1508
60889	4.5055	1325
60888	1.1975	451
60893	0.8309	453
60894	0.3017	157
60891	0.2688	127
60887	0.2047	96
60892	0.1454	50
60886	0.1390	45

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	99.85	gold quality
ileal mucosa	UBERON:0000331	99.70	gold quality
jejunal mucosa	UBERON:0000399	99.58	gold quality
vastus lateralis	UBERON:0001379	99.16	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.67	gold quality
biceps brachii	UBERON:0001507	98.59	gold quality
jejunum	UBERON:0002115	98.51	gold quality
duodenum	UBERON:0002114	98.27	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.21	gold quality
skeletal muscle tissue	UBERON:0001134	97.96	gold quality
quadriceps femoris	UBERON:0001377	97.86	gold quality
colonic mucosa	UBERON:0000317	97.51	gold quality
renal medulla	UBERON:0000362	97.15	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.97	gold quality
deltoid	UBERON:0001476	96.95	gold quality
adult mammalian kidney	UBERON:0000082	96.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.82	gold quality
mucosa of transverse colon	UBERON:0004991	96.76	gold quality
adult organism	UBERON:0007023	96.58	gold quality
rectum	UBERON:0001052	96.42	gold quality
muscle tissue	UBERON:0002385	96.36	gold quality
muscle organ	UBERON:0001630	96.12	gold quality
left ventricle myocardium	UBERON:0006566	95.96	gold quality
epithelial cell of pancreas	CL:0000083	95.92	gold quality
gastrocnemius	UBERON:0001388	95.86	gold quality
liver	UBERON:0002107	95.82	gold quality
pancreatic ductal cell	CL:0002079	95.78	gold quality
muscle of leg	UBERON:0001383	95.62	gold quality
kidney	UBERON:0002113	95.35	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.15	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.92
E-CURD-88	no	504.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting CMBL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-6513-5P	99.43	67.81	1071
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-4316	99.37	65.75	1360

Literature-anchored findings (GeneRIF, showing 2)

• By comparing the enzyme kinetics and chemical inhibition properties between the recombinant protein and tissue preparations, CMBL was shown to be the primary olmesartan medoxomil bioactivating enzyme in the liver and intestine. (PMID:20177059)
• p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP. (PMID:37967006)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cmbl	ENSDARG00000073786
mus_musculus	Cmbl	ENSMUSG00000022235
rattus_norvegicus	Cmbl	ENSRNOG00000011260

Protein

Protein identifiers

Carboxymethylenebutenolidase homolog — Q96DG6 (reviewed: Q96DG6)

All UniProt accessions (1): Q96DG6

UniProt curated annotations — full annotation on UniProt →

Function. Cysteine hydrolase whose endogenous substrates and physiological function are unknown. Catalyzes the hydrolytic activation of several ester-based prodrugs, by cleaving the dioxolone ring to yield their respective active metabolites, diacetyl and CO2. Can thus convert the prodrugs Olmesartan medoxomil and Azilsartan medoxomil into their active metabolites (Olmesartan and Azilsartan), two angiotensin receptor blockers. Is also able to activate beta-lactam antibiotics Faropenem medoxomil and Lenampicillin.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Widely expressed, with highest levels in liver, followed by kidney, small intestine and colon. Present in liver and intestine (at protein level).

Activity regulation. Strongly inhibited by p-chloromercuribenzoate (PCMB). Partially inhibited by bis-p-nitrophenylphosphate (BNPP). Not inhibited by DFP, PMSF, eserine or EDTA.

Similarity. Belongs to the dienelactone hydrolase family.

RefSeq proteins (1): NP_620164* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002925	Dienelactn_hydro	Domain
IPR029058	AB_hydrolase_fold	Homologous_superfamily
IPR042946	CMBL	Family

Pfam: PF01738

Enzyme classification (BRENDA):

• EC 3.1.1.45 — carboxymethylenebutenolidase (BRENDA: 19 organisms, 75 substrates, 31 inhibitors, 42 Km, 41 kcat entries)

Substrate kinetics (BRENDA)

16 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL ACETATE	0.012–0.014	6
TRANS-4-CARBOXYMETHYLENEBUT-2-EN-4-OLIDE	0.015–9.9	6
CIS-4-CARBOXYMETHYLENEBUT-2-EN-4-OLIDE	0.0281–0.59	5
OLMESARTAN MEDOXOMIL	0.16–0.48	5
ALPHA-NAPHTHYL ACETATE	0.02–0.074	4
P-NITROPHENYL ACETATE	0.007–0.021	4
TRANS-DIENELACTONE	0.1017–0.55	3
4-FLUOROMUCONOLACTONE	1.2	1
CIS-4-CARBOXYMETHYLENEBUT-2-CHLORO-2-EN-4-OLIDE	0.0022	1
CIS-4-CARBOXYMETHYLENEBUT-2-METHYL-2-EN-4-OLIDE	0.31	1
FAROPENEM MEDOXOMIL	0.28	1
LENAMPICILLIN	0.063	1
PROTOANEMONIN	0.415	1
4-CARBOXYMETHYLENEBUT-2-EN-4-OLIDE	—	0
E-DIENELACTONE	—	0

UniProt features (13 total): active site 3, modified residue 3, mutagenesis site 2, sequence conflict 2, initiator methionine 1, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DG6-F1	91.92	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 132 (nucleophile); 179; 212

Post-translational modifications (3): 2, 36, 223

Mutagenesis-validated functional residues (2):

Position	Phenotype
132	70% inhibition of enzymatic activity.
132	97% inhibition of enzymatic activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-211945	Phase I - Functionalization of compounds

MSigDB gene sets: 109 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, TSENG_IRS1_TARGETS_DN, SANSOM_APC_TARGETS_DN, BURTON_ADIPOGENESIS_6, CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP, CHICAS_RB1_TARGETS_CONFLUENT, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17, KATSANOU_ELAVL1_TARGETS_UP, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D

GO Biological Process (1): xenobiotic metabolic process (GO:0006805)

GO Molecular Function (1): hydrolase activity (GO:0016787)

GO Cellular Component (3): cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Biological oxidations	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
metabolic process	1
cellular response to xenobiotic stimulus	1
catalytic activity	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1466 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CMBL	ATPSCKMT	Q6P4H8	883
CMBL	BTC	P35070	640
CMBL	AREG	P15514	632
CMBL	EREG	O14944	548
CMBL	LHCGR	P22888	544
CMBL	KRT14	P02533	495
CMBL	ZNF575	Q86XF7	492
CMBL	ROPN1L	Q96C74	476
CMBL	AGTR1	P30556	466
CMBL	PRELID3B	Q9Y3B1	443
CMBL	TK2	O00142	425
CMBL	BLOC1S6	Q9UL45	414
CMBL	IDH2	P48735	408
CMBL	ZNF114	Q8NC26	402
CMBL	SLC16A14	Q7RTX9	401

IntAct

44 interactions, top by confidence:

A	B	Type	Score
RCAN1	PPP3CB	psi-mi:“MI:0914”(association)	0.660
steC	SCD	psi-mi:“MI:0914”(association)	0.460
CMBL	SMARCA2	psi-mi:“MI:0915”(physical association)	0.400
ECE1	CMBL	psi-mi:“MI:0915”(physical association)	0.370
SMS	BAP1	psi-mi:“MI:0914”(association)	0.350
SAP30	BRMS1	psi-mi:“MI:0914”(association)	0.350
Crocc	CLASP2	psi-mi:“MI:0914”(association)	0.350
KIF20B	ACSL3	psi-mi:“MI:0914”(association)	0.350
SNCA	SRRM1	psi-mi:“MI:0914”(association)	0.350
Chmp6	NSF	psi-mi:“MI:0914”(association)	0.350
ECH1	A2ML1	psi-mi:“MI:0914”(association)	0.350
CTCF	ZRANB2	psi-mi:“MI:0914”(association)	0.350
CMBL	H2BC11	psi-mi:“MI:0914”(association)	0.350
TRIM24	DDTL	psi-mi:“MI:0914”(association)	0.350
TSPYL4	CMBL	psi-mi:“MI:0914”(association)	0.350
ZNF514	SRSF10	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
H2AX	ANXA6	psi-mi:“MI:0914”(association)	0.350
CMBL	TRAPPC13	psi-mi:“MI:0914”(association)	0.350
	SYNCRIP	psi-mi:“MI:0914”(association)	0.350
	TUB4q	psi-mi:“MI:0914”(association)	0.350
FAM111A	DFFA	psi-mi:“MI:0914”(association)	0.350
FAM20B	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
GPX8	CMBL	psi-mi:“MI:0914”(association)	0.350
HBB	HNRNPH2	psi-mi:“MI:0914”(association)	0.350
INPP5K	UBR5	psi-mi:“MI:0914”(association)	0.350

BioGRID (92): CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS), CMBL (Affinity Capture-MS)

ESM2 similar proteins: A0A1P8AWH8, A2Y8B9, F1QR43, F4JG10, F4JVN6, F4KFT7, O18756, O22975, O23617, O80574, O80596, O80738, O94923, Q06402, Q0VC13, Q0WUI9, Q10MJ1, Q1PET6, Q3U1V6, Q43093, Q43847, Q5IH13, Q5IH14, Q5MAU8, Q5VS72, Q6DHV7, Q6YXW6, Q6ZHE5, Q80SY6, Q8L7N4, Q8LB01, Q8VYP9, Q8VZF3, Q8W4K1, Q8W519, Q94AH8, Q94AS5, Q94E75, Q96DG6, Q99683

Diamond homologs: O67802, P46209, Q7TP52, Q96DG6, Q5RBU3, Q5XH09, Q6P7K0, Q8R1G2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 60 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
CHD1 and CHD2 subfamily	5	12.7×	3e-03
mRNA Polyadenylation	6	12.3×	9e-04
Processing of Capped Intron-Containing Pre-mRNA	6	11.5×	9e-04
mRNA Splicing - Major Pathway	7	8.9×	9e-04
Dengue Virus-Host Interactions	8	8.5×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	43
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2685147	GRCh37/hg19 5p15.31-15.1(chr5:9002950-15174932)x1	Pathogenic
563031	GRCh37/hg19 5p15.32-14.3(chr5:5830053-19490899)x1	Pathogenic

SpliceAI

884 predictions. Top by Δscore:

Variant	Effect	Δscore
5:10282195:A:AC	donor_gain	1.0000
5:10282195:ACGT:A	donor_gain	1.0000
5:10282196:C:CC	donor_gain	1.0000
5:10282196:CGTC:C	donor_gain	1.0000
5:10282198:T:TA	donor_gain	1.0000
5:10282286:TGC:T	acceptor_gain	1.0000
5:10282287:GC:G	acceptor_gain	1.0000
5:10282288:CC:C	acceptor_gain	1.0000
5:10282289:C:CC	acceptor_gain	1.0000
5:10282289:CTGAA:C	acceptor_loss	1.0000
5:10282290:T:A	acceptor_loss	1.0000
5:10288525:TGGTT:T	acceptor_gain	1.0000
5:10290546:A:AC	donor_gain	1.0000
5:10290547:C:CC	donor_gain	1.0000
5:10290559:T:A	donor_gain	1.0000
5:10290782:C:CC	acceptor_gain	1.0000
5:10282195:ACGTC:A	donor_gain	0.9900
5:10282196:CGT:C	donor_gain	0.9900
5:10282196:CGTCC:C	donor_gain	0.9900
5:10282284:AATGC:A	acceptor_gain	0.9900
5:10282285:ATGC:A	acceptor_gain	0.9900
5:10288415:AACTC:A	donor_loss	0.9900
5:10288417:CTC:C	donor_loss	0.9900
5:10288418:TCA:T	donor_loss	0.9900
5:10288419:C:CG	donor_loss	0.9900
5:10288420:A:AT	donor_loss	0.9900
5:10288526:GGTT:G	acceptor_gain	0.9900
5:10288528:TT:T	acceptor_gain	0.9900
5:10288530:C:CC	acceptor_gain	0.9900
5:10290537:TTTA:T	donor_gain	0.9900

AlphaMissense

1623 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:10280549:G:C	F214L	0.997
5:10280549:G:T	F214L	0.997
5:10280551:A:G	F214L	0.997
5:10290614:T:A	D50V	0.993
5:10280570:A:C	F207L	0.991
5:10280570:A:T	F207L	0.991
5:10280572:A:G	F207L	0.991
5:10286427:G:C	F131L	0.989
5:10286427:G:T	F131L	0.989
5:10286429:A:G	F131L	0.989
5:10290614:T:G	D50A	0.986
5:10290615:C:G	D50H	0.984
5:10290623:A:T	V47D	0.981
5:10290603:A:G	W54R	0.980
5:10290603:A:T	W54R	0.980
5:10286428:A:G	F131S	0.977
5:10286431:C:T	G130E	0.977
5:10282220:C:G	D179H	0.976
5:10286419:C:A	G134V	0.976
5:10286423:A:G	W133R	0.976
5:10286423:A:T	W133R	0.976
5:10286424:G:C	C132W	0.975
5:10290607:A:C	F52L	0.975
5:10290607:A:T	F52L	0.975
5:10290609:A:G	F52L	0.975
5:10280555:A:C	H212Q	0.974
5:10280555:A:T	H212Q	0.974
5:10286426:A:G	C132R	0.974
5:10280473:A:G	W240R	0.973
5:10280473:A:T	W240R	0.973

dbSNP variants (sampled 300 via entrez): RS1000141452 (5:10297772 G>A), RS1000246047 (5:10292018 A>G), RS1000385478 (5:10296421 C>T), RS1000404757 (5:10281837 C>A,T), RS1000417614 (5:10296159 A>T), RS1000441777 (5:10303559 G>A,T), RS1000590121 (5:10303200 T>G), RS1000630570 (5:10281985 C>T), RS1000776413 (5:10301947 G>A,C), RS1000841407 (5:10304055 C>T), RS1000872713 (5:10303706 T>C), RS1000920222 (5:10279735 T>C), RS1001327409 (5:10304767 A>G,T), RS1001510966 (5:10291515 G>A), RS1001549687 (5:10296274 G>A)

Disease associations

OMIM: gene MIM:613379 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_720	Metabolite levels	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010532	salicylurate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066502 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.28	Kd	52.35	nM	CHEMBL5653589
7.25	ED50	56.09	nM	CHEMBL5653589
6.20	Kd	626.6	nM	CHEMBL3752910
6.17	ED50	671.4	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148093: Binding affinity to human CMBL incubated for 45 mins by Kinobead based pull down assay	kd	0.0524	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148093: Binding affinity to human CMBL incubated for 45 mins by Kinobead based pull down assay	kd	0.6266	uM

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	6
Cisplatin	affects expression, affects cotreatment, increases expression	4
Aflatoxin B1	affects expression, decreases expression, increases expression	4
Cyclosporine	affects expression, decreases expression	3
bisphenol A	decreases expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Arsenic	affects methylation, increases abundance, increases expression	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Formaldehyde	decreases expression, increases expression	2
Testosterone	decreases expression, increases expression	2
Valproic Acid	affects expression, decreases expression	2
Cadmium Chloride	increases expression	2
bisphenol F	increases expression	1
bufotalin	decreases expression	1
chloroacetaldehyde	increases expression	1
lead acetate	affects cotreatment, increases expression	1
sodium arsenate	increases abundance, increases expression	1
zinc protoporphyrin	affects cotreatment, increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
aflatoxin B2	decreases methylation	1
nickel sulfate	increases expression	1
beta-methylcholine	affects expression	1
pentanal	decreases expression	1
adefovir dipivoxil	increases expression	1
K 7174	decreases expression	1
nutlin 3	increases secretion, affects cotreatment	1
bisphenol B	increases expression	1
abrine	decreases expression	1
bisphenol S	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651135	Binding	Binding affinity to human CMBL incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.